Drug Target Review

SEPTEMBER 22, 2023

The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 billion by 2030. Nat Rev Bioeng [Internet]. 2023 Jan 19;1(1):32–45. 95: 729–38

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

Vial

MAY 20, 2024

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. What is a Pre-Clinical CRO? between 2024 and 2030. over this period.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

Vial

APRIL 18, 2024

The urgency for novel therapeutic approaches makes ophthalmology a rapidly growing domain of clinical research. Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding.

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

Olympian Clinical Research

JULY 12, 2022

There are several types of depression, each with its own set of symptoms and recommended treatment methods. Major depressive disorder ( MDD ), also known as clinical depression, is characterized by a persistent feeling of sadness or emptiness lasting for at least two weeks. As a result, many people do not seek treatment.

Clinical Research 94

Clinical Research Doctors Treatment Research 94

Vial

FEBRUARY 15, 2024

According to the 2022 Polaris Market Research Report , the global clinical trials outsourcing market reached USD 38.11 over the forecast period (2022-2030). This article discusses current challenges in managing clinical trials and elucidates the pivotal role that CROs play in overcoming these obstacles.

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

The Pharma Data

SEPTEMBER 28, 2020

Less than 1% of affected individuals receive proper anti-parasitic treatment 11 , and current drugs are inadequate to fight the entire spectrum of the disease. Against this background, Novartis is pursuing an end-to-end approach, with activity on three fronts: drug discovery, clinical research and healthcare system strengthening.

Disease 52

Disease Therapies Treatment Clinical Research 52

Codon

OCTOBER 27, 2024

In 2014, the World Health Organization (WHO) proposed an initiative called the End TB Strategy , aimed at reducing cases by 80 percent, deaths by 90 percent, and diagnostic/treatment costs by 100 percent by 2030. In The Magic Mountain , patients receiving this treatment joined what they dubbed the “Half-Lung Club.”

Immune Response 77

Immune Response Doctors Disease Laboratories 77